胆管上皮细胞TGR5下调促进硬化性胆管炎发病
该研究探讨胆汁酸受体TGR5在原发性硬化性胆管炎(PSC)发病中的作用。在PSC患者和Abcb4-/-小鼠胆管上皮细胞中TGR5表达降低,IL8同源物可下调TGR5,而TGR5过表达可逆转炎症表型,norUDCA可恢复TGR5表达。
要点
- PSC患者和Abcb4-/-小鼠胆管上皮细胞TGR5表达降低。
- IL8/IL8同源物下调胆管上皮细胞TGR5 mRNA和蛋白水平。
- norUDCA可恢复Abcb4-/-小鼠胆管上皮细胞TGR5表达。
核心结论
- 胆管上皮细胞TGR5表达降低促进反应性表型、加重胆管损伤,参与硬化性胆管炎发病。
- norUDCA恢复胆管TGR5表达是其先前未知的作用机制。
研究设计与样本
- 分析PSC肝脏、Abcb4-/-小鼠模型及UDCA或norUDCA喂养的Abcb4-/-小鼠的TGR5表达与定位。
- 研究IL8/IL8同源物对TGR5 mRNA和蛋白水平的影响。
- 通过单细胞转录组学分析不同小鼠模型的胆管上皮细胞基因表达。
主要发现
- PSC和Abcb4-/-肝脏胆管上皮细胞中TGR5 mRNA表达和免疫荧光染色强度降低,Abcb4-/-肝外胆管亦降低,但肝内巨噬细胞无变化。
- 其他肝病包括原发性胆汁性胆管炎的肝组织中胆管上皮细胞TGR5荧光强度无变化。
- IL8/IL8同源物而非其他细胞因子孵育降低胆管上皮细胞TGR5 mRNA和蛋白水平。
- Abcb4-/-小鼠胆管上皮细胞磷酸化Erk水平降低,Icam1、Vcam1和Tgfβ2表达升高;Tgr5过表达可消除Abcb4-/-胆管上皮细胞的活化炎症表型。
- norUDCA喂养恢复Abcb4-/-肝脏胆管上皮细胞TGR5表达水平。
临床怎么用
- TGR5表达下调与PSC胆管损伤相关,提示其作为潜在治疗靶点。
- norUDCA可能通过恢复胆管TGR5表达发挥作用,支持其用于PSC治疗的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is characterized by chronic inflammation and progressive fibrosis of the biliary tree. The bile acid receptor TGR5 (GPBAR1) is found on biliary epithelial cells (BECs), where it promotes secretion, proliferation and tight junction integrity. Thus, we speculated that changes in TGR5-expression in BECs may contribute to PSC pathogenesis. METHODS: TGR5-expression and -localization were analyzed in PSC livers and liver tissue, isolated bile ducts and BECs from Abcb4-/-, Abcb4-/-/Tgr5Tg and ursodeoxycholic acid (UDCA)- or 24-norursodeoxycholic acid (norUDCA)-fed Abcb4-/- mice. The effects of IL8/IL8 homologues on TGR5 mRNA and protein levels were studied. BEC gene expression was analyzed by single-cell transcriptomics (scRNA-seq) from distinct mouse models. RESULTS: TGR5 mRNA expression and immunofluorescence staining intensity were reduced in BECs of PSC and Abcb4-/- livers, in Abcb4-/- extrahepatic bile ducts, but not in intrahepatic macrophages. No changes in TGR5 BEC fluorescence intensity were detected in liver tissue of other liver diseases, including primary biliary cholangitis. Incubation of BECs with IL8/IL8 homologues, but not with other cytokines, reduced TGR5 mRNA and protein levels. BECs from Abcb4-/- mice had lower levels of phosphorylated Erk and higher expression levels of Icam1, Vcam1 and Tgfβ2. Overexpression of Tgr5 abolished the activated inflammatory phenotype characteristic of Abcb4-/- BECs. NorUDCA-feeding restored TGR5-expression levels in BECs in Abcb4-/- livers. CONCLUSIONS: Reduced TGR5 levels in BECs from patients with PSC and Abcb4-/- mice promote development of a reactive BEC phenotype, aggravate biliary injury and thus contribute to the pathogenesis of sclerosing cholangitis. Restoration of biliary TGR5-expression levels represents a previously unknown mechanism of action of norUDCA. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease-associated with progressive inflammation of the bile duct, leading to fibrosis and end-stage liver disease. Bile acid (BA) toxicity may contribute to the development and disease progression of PSC. TGR5 is a membrane-bound receptor for BAs, which is found on bile ducts and protects bile ducts from BA toxicity. In this study, we show that TGR5 levels were reduced in bile ducts from PSC livers and in bile ducts from a genetic mouse model of PSC. Our investigations indicate that lower levels of TGR5 in bile ducts may contribute to PSC development and progression. Furthermore, treatment with norUDCA, a drug currently being tested in a phase III trial for PSC, restored TGR5 levels in biliary epithelial cells.
引用
- Reich M, Spomer L, Klindt C, et al. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. J Hepatol. 2021. PMID: 33872692. doi:10.1016/j.jhep.2021.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。